Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study
Lars M. Wagner(Cincinnati Children's Hospital Medical Center), Peter C. Adamson(Children's Hospital of Philadelphia), Susan M. Blaney(Center for Cancer and Blood Disorders), Matthew M. Ames(Mayo Clinic), Marvin D. Nelson(Children's Hospital of Los Angeles), John P. Perentesis(Cincinnati Children's Hospital Medical Center), Stephanie L. Safgren(Mayo Clinic), Ashish M. Ingle(Arcadia), Joel M. Reid(Children's Hospital of Philadelphia)
Cited by 73
Related Papers
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
|JAMA Oncology|2022|557
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children
|New England Journal of Medicine|2020|308
Renal Carcinomas With the t(6;11)(p21;q12)
|The American Journal of Surgical Pathology|2005|290
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
|Journal of Clinical Oncology|2012|231